PRA Health Sciences (PRAH) Tops Q3 EPS by 6c, Offers FY Guidance

PRA Health Sciences (NASDAQ: PRAH) reported Q3 EPS of $1.13, $0.06 better than the analyst estimate of $1.07. Revenue for the quarter came in at $717.6 million versus the consensus estimate of $726.88 million.

GUIDANCE:

PRA Health Sciences sees FY2018 EPS of $4.22-$4.27, versus the consensus of $4.19. PRA Health Sciences sees FY2018 revenue of $2.87-2.92 billion, versus the consensus of $2.91 billion.

For earnings history and earnings-related data on PRA Health Sciences (PRAH) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• The LGL Group (LGL) Misses Q2 EPS by 8c
• InspireMD (NSPR) Tops Q2 EPS by 1c